Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 7, 2005, Pages 1470-1474

  Loew, Michael ^a   Hoffmann, Michael M ^b   Koenig, Wolfgang ^c   Brenner, Hermann ^a   Rothenbacher, Dietrich ^a  

^a GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Coronary heart disease; Cystatin C; Genotype; Prognosis; Prospective study

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXON; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; STROKE;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; CYSTATINS; EXONS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK FACTORS;

EID: 21544476972     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000168416.74206.62     Document Type: Article

References (16)

1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM. Pajak A for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA. Project-registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90: 583-612.
2. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, Muhlestein JB, Granger CB. Genetics of coronary heart disease: Current knowledge and research principles. Am Heart J. 2000;140:S11-S26.
3. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90: 251-262.
4. Shi G-P, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999;104:1191-1197.
5. Abrahamson M, Grubb A, Olafsson I, Lundwall A. Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C. FEBS Lett. 1987;216:229-233.
6. Eriksson P, Deguch Hi, Samnegård A, Lundman P, Boquist S, Tornvall P, Ericsson CG, Bergstrand L, Hansson LO, Ye S, Hamsten A. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol. 2004;24: 551-557.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
8. nd ed. Baltimore. John Hopkins University Press 1991.
9. Albert MA, Rifai N, Ridker PM. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Medicine. 2001;6:145-149.
10. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110: 2342-2348.
11. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-327.
12. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D. Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416-1421.
13. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102: 576-583.
14. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, Shi GP. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111:897-906.
15. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: Part I: New genes and pathways. Circulation. 2004;110:1868-1873.
16. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: Part II: Clinical implications. Circulation. 2004;110:2066-2071.